What Elucid Bioimaging does
Elucid makes AI-powered, histology-validated software that analyzes CT scans to characterize plaque in coronary and carotid arteries, helping cardiologists and radiologists assess cardiovascular disease risk and guide treatment. Its Plaque-IQ product identifies high-risk plaque features such as lipid-rich necrotic core, and the company is also developing an FFR-CT analysis tool currently under FDA review. Elucid says roughly 70% of insured lives in the US have coverage policies for its plaque assessment. The company was founded in 2013 and is based in Boston.
Elucid Bioimaging is a healthcare tool on Falcoscan. AI software that reads CT scans to assess heart-disease risk from arterial plaque. Falcoscan rates Elucid Bioimaging with an Opportunity score of 86/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: hot. Elucid Bioimaging is founded in 2013, currently at Series_d_plus stage. Pricing: Paid.